Drive Medical claimed the top prize at the third annual SRS Shark Tank 2026, held during the Society of Robotic Surgery's annual conference at the Diplomat Beach Resort in Hollywood, Florida. The event, a collaboration between SRS and Puma Venture Capital, once again showcased cutting-edge innovations in the digital and robotic surgery ecosystem and featured early-stage companies poised to transform minimally invasive care.
HOLLYWOOD, Fla., Sept. 5, 2026 /PRNewswire-PRWeb/ -- Drive Medical claimed the top prize at the third annual SRS Shark Tank 2026, held during the Society of Robotic Surgery's annual conference at the Diplomat Beach Resort in Hollywood, Florida. The event, a collaboration between SRS and Puma Venture Capital, once again showcased cutting-edge innovations in the digital and robotic surgery ecosystem and featured early-stage companies poised to transform minimally invasive care.
SRS Shark Tank 2026 featured presentations from nine innovative companies. Each had five minutes to pitch their technology and five minutes to engage in a Q&A session with a panel of esteemed judges, including top surgeons, investors, and medical device experts. Companies were evaluated on innovation, impact on healthcare, market potential, business model, and presentation.
Drive Medical earned the top honor for the Pollywog System, the first easy-to-use robotic endoscope integrated with artificial intelligence. The platform is designed to give physicians faster, safer access to the small bowel, allowing diagnosis and treatment to be completed in a single session rather than across multiple procedures.
DeepQure secured second place with HyperQure, the world's first extravascular renal denervation system for resistant hypertension. Delivered laparoscopically, the device wraps the renal artery from the outside to achieve complete denervation while avoiding the vessel lining.
Microsure came in third with MUSA-3, a microsurgical robot that downscales and stabilizes a surgeon's hand movements during open super-microsurgical procedures, including free flap, lymphatic, and peripheral nerve surgery. The system received CE mark approval earlier this year.
The strength of the 2026 field extended well beyond the podium: every one of the nine presenting companies was placed in the top three by at least one judge. Reveal Surgical presented optical imaging technology that characterizes tissue for tumor assessment during surgery, and Symphera demonstrated a laparoscopic system that lets surgeons switch instrument tips at the push of a button. Tioga Cardiovascular showed its transcatheter approach to mitral and tricuspid valve replacement.
CardioSentry presented an AI platform for autonomous cardiac ultrasound, and Nina Medical showcased a completely non-invasive treatment for benign prostatic hyperplasia. LITLab rounded out the slate with mobile, high-fidelity surgical training labs that travel to health systems and medtech companies to train clinical teams onsite. Together the group reflected an unusually broad and competitive slate, spanning robotics, imaging, structural heart, urology, and surgical education.
The 2026 judging panel included Steve Bell, Rob Morgan, Dr. Santiago Horgan, Dr. Erik B. Wilson, Scott Zinober, and Babak Tehranchi, and the event was co-chaired by Amit Hazan and Dr. Vipul Patel.
Participating companies included:
Microsure, Symphera, LITLab, Reveal Surgical, DeepQure, Drive Medical, Nina Medical, CardioSentry, and Tioga Cardiovascular.
About the Society of Robotic Surgery:
Founded in 2012, the Society of Robotic Surgery (SRS) is guided by the fundamental principles of education and collaboration as a means to tackle the complex issues of robotic surgery. The SRS' membership includes more than 20,000 physicians of all disciplines from around the world whose mission is to share information related to multi-centric studies, database collection, fellowship training and funding support related to robotic surgery. The SRS is the only multi-specialty robotic surgery society in the world with an annual meeting that includes updates in more than a dozen medical sub-specialties along with state-of-the-art plenary sessions and hot topic courses.
About Puma Venture Capital:
Puma Venture Capital is an investment firm seeking to leverage its surgeon venture partners to invest in all aspects of physical intelligence across every medical procedure — to improve patient outcomes, lift labor productivity, and lower system costs.
Media Contact
Ryan Julison, Society of Robotic Surgery, 1 3213776877, [email protected]
SOURCE Society of Robotic Surgery
Share this article